Fukami Maki, Seki Atsuhito, Ogata Tsutomu
Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Hamamatsu, Japan.
Department of Orthopedic Surgery, National Center for Child Health and Development, Tokyo, Japan.
Mol Syndromol. 2016 Apr;7(1):3-11. doi: 10.1159/000444596. Epub 2016 Mar 15.
SHOX in the short arm pseudoautosomal region (PAR1) of sex chromosomes is one of the major growth genes in humans. SHOX haploinsufficiency results in idiopathic short stature and Léri-Weill dyschondrosteosis and is associated with the short stature of patients with Turner syndrome. The SHOX protein likely controls chondrocyte apoptosis by regulating multiple target genes including BNP,Fgfr3, Agc1, and Ctgf. SHOX haploinsufficiency frequently results from deletions and duplications in PAR1 involving SHOX exons and/or the cis-acting enhancers, while exonic point mutations account for a small percentage of cases. The clinical severity of SHOX haploinsufficiency reflects hormonal conditions rather than mutation types. Growth hormone treatment seems to be beneficial for cases with SHOX haploinsufficiency, although the long-term outcomes of this therapy require confirmation. Future challenges in SHOX research include elucidating its precise function in the developing limbs, identifying additional cis-acting enhancers, and determining optimal therapeutic strategies for patients.
位于性染色体短臂假常染色体区域(PAR1)的SHOX基因是人类主要的生长基因之一。SHOX单倍剂量不足会导致特发性身材矮小和Léri-Weill软骨发育不全,并与特纳综合征患者的身材矮小有关。SHOX蛋白可能通过调控包括BNP、Fgfr3、Agc1和Ctgf在内的多个靶基因来控制软骨细胞凋亡。SHOX单倍剂量不足通常是由PAR1中涉及SHOX外显子和/或顺式作用增强子的缺失和重复引起的,而外显子点突变占病例的比例较小。SHOX单倍剂量不足的临床严重程度反映的是激素状况而非突变类型。生长激素治疗似乎对SHOX单倍剂量不足的病例有益,尽管该疗法的长期效果尚需证实。SHOX研究未来面临的挑战包括阐明其在四肢发育中的精确功能、识别其他顺式作用增强子以及确定针对患者的最佳治疗策略。